Stock Taper 
Bicara Therapeutics Inc., a Boston-based subsidiary of Biocon, develops bifunctional therapies like ficerafusp alfa for solid tumors, combining EGFR targeting with TGF-β binding, and is a clinical-stage biopharma founded in 2018.
Ficerafusp alfa, Bicara Therapeutics' lead dual-action antibody targeting EGFR and TGF-β, is an investigational therapy in clinical trials for solid tumors, including head and neck cancer, with FDA Breakthrough Therapy Designation.
In a pivotal moment for the company, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for Bicara's lead drug candidate, ficerafusp alfa, for the first-line treatment of a specific type of head and neck cancer. This designation is intended to expedite the development and review of drugs for serious conditions and was supported by promising data from the company's Phase 1/1b clinical trials.
In 2025, Bicara Therapeutics made a significant strategic shift by advancing its lead drug candidate, ficerafusp alfa, into a pivotal Phase 2/3 clinical trial (FORTIFI-HN01) for the treatment of head and neck squamous cell carcinoma (HNSCC). This decision was substantially validated in October 2025 when the U.S. FDA granted Breakthrough Therapy Designation for ficerafusp alfa in this indication, signaling a strong belief in its potential to be a significant improvement over existing therapies and accelerating its development and review timeline.
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on October 1, 2026 to two new employees as a material inducement to employment under Bicara's 2026 Inducement Plan.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 TNGX | $21.56 | COMPARE |
 FTRE | $21.59 | COMPARE |
 SEPN | $35.87 | COMPARE |
 MRVI | $8.15 | COMPARE |
 SVRA | $4.65 | COMPARE |
 CGEM | $15.46 | COMPARE |
 KURA | $10.57 | COMPARE |
 PRME | $3.52 | COMPARE |
